Initial Data of LUCIDITY Study
Recent News
LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
Dec 02, 2022
TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
Nov 14, 2022
TauRx Pharmaceuticals Ltd has announced further results from its Phase 3 LUCIDITY trial for Hydromethylthionine mesylate (HMTM)
Oct 06, 2022
TauRx Pharmaceuticals Ltd is delighted to name Dr Richard Stefanacci, an established global key opinion leader in Alzheimer’s, as Chief Medical Officer (CMO)
Oct 06, 2022